Abstract
Background All current human immunodeficiency virus (HIV) vaccine candidates contain multiple viral components and elicit antibodies that react positively in licensed HIV diagnostic tests. Thus, vaccine trial participants could be falsely diagnosed as infected with HIV and it is a major public health concern for volunteers who want to participate in future HIV vaccine trials. Additionally, uninfected, seropositive vaccinees may encounter long-term social and economic harms. Moreover, this also interferes with early detection of true HIV infections during preventive HIV vaccine trials. Based on the increased number of HIV vaccines being tested globally, it is essential to differentiate vaccine – from virus-induced antibodies.
Highlights
All current human immunodeficiency virus (HIV) vaccine candidates contain multiple viral components and elicit antibodies that react positively in licensed HIV diagnostic tests
Vaccine trial participants could be falsely diagnosed as infected with HIV and it is a major public health concern for volunteers who want to participate in future HIV vaccine trials
We established a new HIV-serodetection assay termed HIV-SELECTEST was developed based on these peptides that distinguishes between vaccine-induced antibodies and seroconversion following HIV infections
Summary
HIV-SELECTEST EIA and rapid test: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. Address: 1CBER, Food and Drug Administration, Bethesda, MD, USA, 2Blood Systems Research Institute, San Francisco, CA, USA, 3Center for the AIDS Programme of Research in South Africa, Durban, South Africa, 4Emory Vaccine Research Center, Atlanta, GA, USA and 5CBER, FDA, Bethesda, MD, USA. Published: 22 October 2009 Retrovirology 2009, 6(Suppl 3):P192 doi:10.1186/1742-4690-6-S3-P192. AIDS Vaccine 2009 Anna Laura Ross Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
